# PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Study · id `cardio:ct-nct04889872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04889872](<https://clinicaltrials.gov/study/NCT04889872>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04889872

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2250 participants.

## Technical summary

Registry record NCT04889872. Randomized; no masking; primary purpose treatment. Start 2021-10-12 (actual); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2250 participants (planned count; ClinicalTrials.gov record NCT04889872, source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)
- Started: 2021-10-12 (actual) (ClinicalTrials.gov record NCT04889872, source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT04889872, source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)
- Completion: 2037-06 (anticipated) (ClinicalTrials.gov record NCT04889872, source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; Japan; Netherlands; Switzerland (ClinicalTrials.gov record NCT04889872, source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04889872-2025-12-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- Acronym: PROGRESS
- Condition: Aortic Stenosis, Calcific
- Condition: Aortic Valve Stenosis
- Intervention (Device): SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: b83d6e5bb1e6a284a6d93aacb00bc5938598800bb4fc21edf1c0ab395bc628b5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
